CHI3L1 and Alzheimer disease: Further, in 2015, Wennström et al. reported that CSF YKL-40 was elevated in AD subjects, but not in those with Parkinson’s disease or DLB, thus making it a potential distinguishing biomarker between these neurological disorders (77).